KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) Files An 8-K Results of Operations and Financial Condition
On December 3, 2019, KalVista Pharmaceuticals, Inc. (the “Company”) reported its financial results for the fiscal quarter ended October 31, 2019. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.
The information furnished with Item 2.02 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
KalVista Pharmaceuticals, Inc. Exhibit
EX-99.1 2 kalv-ex991_6.htm EX-99.1 kalv-ex991_6.htm Exhibit 99.1 KalVista Pharmaceuticals Reports Fiscal Second Quarter Results – KVD900 Phase 2 Trial Data for On-Demand Treatment of HAE Expected in 2020 – – KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME) Data Expected This Month – – KVD900 Receives FDA Fast Track Designation – Cambridge,…
To view the full exhibit click here
About KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV)
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
